These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37241059)

  • 1. Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report.
    Tian Y; Hu W; Yan Q; Feng B
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241059
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world safety and effectiveness of dapagliflozin in people living with type 1 diabetes in Spain: The Dapa-ON multicenter retrospective study.
    Durán-Martínez M; Azriel S; Doulatram-Gamgaram VK; Moreno-Pérez Ó; Pinés-Corrales PJ; Tejera-Pérez C; Merino-Torres JF; Brito-Sanfiel M; Chico A; Marco A; García-Fernández E; Martínez-Montoro JI;
    Diabetes Metab; 2024 Jan; 50(1):101501. PubMed ID: 38061425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 4. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
    Lee IH; Ahn DJ
    Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes.
    Urakami T; Yoshida K; Suzuki J
    Intern Med; 2023; 62(2):177-186. PubMed ID: 36642532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
    Elian V; Popovici V; Karampelas O; Pircalabioru GG; Radulian G; Musat M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy.
    Chou WY; Li YR; Chan WK; Chen ST
    Biomed J; 2018 Dec; 41(6):348-355. PubMed ID: 30709576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
    Kamoshima H; Nomoto H; Yamashita K; Takahashi Y; Tsuchida K; Kuwabara S; Miya A; Cho KY; Kameda H; Nakamura A; Atsumi T; Taneda S; Kurihara Y; Aoki S; Ono Y; Miyoshi H
    Endocr J; 2022 May; 69(5):495-509. PubMed ID: 34819409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies.
    Ma Y; Zhao Q; Peng H; Nalisa DL; Shan P; Jiang H
    Front Biosci (Landmark Ed); 2023 May; 28(5):98. PubMed ID: 37258468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
    Edwards K; Li X; Lingvay I
    J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
    Li Y; Li H; Dong L; Lin D; Xu L; Lou P; Zang D; Wang K; Ma L
    Front Endocrinol (Lausanne); 2022; 13():923376. PubMed ID: 35872994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.